Eli Lilly的体重损失和糖尿病治疗由于批发商库存减少和竞争而使Q3销售额低于预期。 Eli Lilly's weight loss and diabetes treatments saw weaker-than-expected Q3 sales due to wholesaler inventory reductions and competition.

Elilly报告说,尽管从短缺中恢复,但第三季度的减重药品Zepbound和糖尿病治疗Mounjaro销售量低于预期。 Eli Lilly reported weaker-than-expected sales for its weight loss drug Zepbound and diabetes treatment Mounjaro in the third quarter, despite recovering from shortages. 该公司将这一点归因于批发商减少了库存,尽管分析家认为,复合版本的竞争也可能是一个因素。 The company attributed this to wholesalers reducing inventory, though analysts suggest competition from compounded versions may also be a factor. Elilly保持了强劲的基本需求,并已投资100至150亿美元提高制造业能力。 Eli Lilly maintains strong underlying demand and has invested $10-$15 billion to enhance manufacturing capacity.